- Home
- AOMR vs SGMT Comparison
AOMR vs SGMT Comparison
Compare AOMR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- SGMT
- Stock Information
- Founded
- AOMR 2018
- SGMT 2006
- Country
- AOMR United States
- SGMT United States
- Employees
- AOMR N/A
- SGMT N/A
- Industry
- AOMR Real Estate Investment Trusts
- SGMT
- Sector
- AOMR Real Estate
- SGMT
- Exchange
- AOMR Nasdaq
- SGMT Nasdaq
- Market Cap
- AOMR 225.8M
- SGMT 269.2M
- IPO Year
- AOMR 2021
- SGMT 2023
- Fundamental
- Price
- AOMR $9.37
- SGMT $8.42
- Analyst Decision
- AOMR Strong Buy
- SGMT Strong Buy
- Analyst Count
- AOMR 7
- SGMT 6
- Target Price
- AOMR $11.57
- SGMT $26.83
- AVG Volume (30 Days)
- AOMR 60.7K
- SGMT 801.2K
- Earning Date
- AOMR 08-05-2025
- SGMT 08-13-2025
- Dividend Yield
- AOMR 13.57%
- SGMT N/A
- EPS Growth
- AOMR N/A
- SGMT N/A
- EPS
- AOMR 1.51
- SGMT N/A
- Revenue
- AOMR $57,147,000.00
- SGMT N/A
- Revenue This Year
- AOMR N/A
- SGMT N/A
- Revenue Next Year
- AOMR $10.94
- SGMT N/A
- P/E Ratio
- AOMR $6.24
- SGMT N/A
- Revenue Growth
- AOMR N/A
- SGMT N/A
- 52 Week Low
- AOMR $7.36
- SGMT $1.73
- 52 Week High
- AOMR $12.61
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- AOMR 39.18
- SGMT 46.59
- Support Level
- AOMR $9.30
- SGMT $7.98
- Resistance Level
- AOMR $9.69
- SGMT $11.41
- Average True Range (ATR)
- AOMR 0.16
- SGMT 0.80
- MACD
- AOMR -0.04
- SGMT -0.29
- Stochastic Oscillator
- AOMR 17.44
- SGMT 13.41
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.